ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer
March 11, 2019Roche's Genentech unit on Friday announced that the FDA granted accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for use in adults with PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast ca -
NICE recommends MSD's Keytruda for advanced PD-L1-positive lung cancer
June 07, 2018UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS for the treatment of previously untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adult patients.
Pharma Sources Insight January 2025
